{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:00:55Z","timestamp":1792461655843,"version":"4.5.0"},"reference-count":55,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["Indian J Dermatol Venereol Leprol"],"abstract":"<jats:p>Upadacitinib, a second-generation oral Janus kinase (JAK) inhibitor, selectively targets the JAK 1 non-receptor protein kinase, effectively modulating downstream inflammatory pathways implicated in a range of dermatological diseases. Its JAK 1 selectivity mitigates unwanted side effects associated with broader JAK inhibition. FDA approval for moderate to severe atopic dermatitis (AD) in January 2022 marked a significant milestone, expanding treatment options in dermatology. Since then, upadacitinib has demonstrated efficacy in various dermatological disorders, contributing to improved patient outcomes. This review aims to spotlight its use in AD, as well as off-label indications in dermatology, its safety and efficacy profile, and pertinent information regarding side effects and contraindications.<\/jats:p>","DOI":"10.25259\/ijdvl_133_2025","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:05:31Z","timestamp":1760360731000},"page":"68-76","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Upadacitinib in dermatology: A systematic review of mechanism, current applications, efficacy, safety, and emerging evidence"],"prefix":"10.25259","volume":"92","author":[{"given":"Sunil","family":"Dogra","sequence":"first","affiliation":[{"name":"Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thammannagowda","family":"Prarthana","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaikwad","family":"Sudharani","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Chhabra","sequence":"additional","affiliation":[{"name":"Department of Immunopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"10.25259\/IJDVL_133_2025\/ref-1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol"},{"key":"10.25259\/IJDVL_133_2025\/ref-2","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: Results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"10.25259\/IJDVL_133_2025\/ref-3","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/cpdd.462","article-title":"Pharmacokinetics of upadacitinib with the clinical regimens of the extended-release formulation utilized in rheumatoid arthritis phase 3 trials","volume":"8","author":"Mohamed","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.25259\/IJDVL_133_2025\/ref-4","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.ad.2017.10.012","article-title":"Dupilumab for the treatment of atopic dermatitis","volume":"109","author":"Ferreira","year":"2018","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"10.25259\/IJDVL_133_2025\/ref-5","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/j.jaci.2015.01.048","article-title":"IL-33 impacts on the skin barrier by downregulating the expression of filaggrin","volume":"135","author":"Seltmann","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.25259\/IJDVL_133_2025\/ref-6","doi-asserted-by":"crossref","first-page":"e15636","DOI":"10.1111\/dth.15636","article-title":"Comparative efficacy and safety of abrocitinib, baricitinib and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis","volume":"35","author":"Wan","year":"2022","journal-title":"Dermatologic Therapy"},{"key":"10.25259\/IJDVL_133_2025\/ref-7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/LEXB9006","article-title":"Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis","volume":"28","author":"Edwards","year":"2024","journal-title":"Health Technol Assess"},{"key":"10.25259\/IJDVL_133_2025\/ref-8","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: A randomized clinical trial","volume":"157","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.25259\/IJDVL_133_2025\/ref-9","article-title":"Rinvoq (upadacitinib) extended-release tablets, for oral use: Highlights of prescribing information [Internet]","author":"U.S. Food and Drug Administration","year":"2023"},{"key":"10.25259\/IJDVL_133_2025\/ref-10","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.jaci.2021.07.036","article-title":"Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results","volume":"149","author":"Silverberg","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.25259\/IJDVL_133_2025\/ref-11","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): Results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet"},{"key":"10.25259\/IJDVL_133_2025\/ref-12","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): A randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"Lancet"},{"key":"10.25259\/IJDVL_133_2025\/ref-13","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","article-title":"Safety of janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: A systematic review and meta-analysis","volume":"158","author":"Olivera","year":"2020","journal-title":"Gastroenterology"},{"key":"10.25259\/IJDVL_133_2025\/ref-14","doi-asserted-by":"publisher","first-page":"e002735","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"key":"10.25259\/IJDVL_133_2025\/ref-15","doi-asserted-by":"publisher","first-page":"e003392","DOI":"10.1136\/rmdopen-2023-003392","article-title":"MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis","volume":"9","author":"Charles-Schoeman","year":"2023","journal-title":"RMD Open"},{"key":"10.25259\/IJDVL_133_2025\/ref-16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jdcr.2023.11.023","article-title":"Upadacitinib as a treatment for co-existent allergic contact dermatitis and psoriasis","volume":"44","author":"C\u07e3, en","year":"2023","journal-title":"JAAD Case Rep"},{"key":"10.25259\/IJDVL_133_2025\/ref-17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jdcr.2023.06.024","article-title":"Efficacy and tolerence of upadacitinib in the treatment of dyshidrotic eczema","volume":"38","author":"Kiszla","year":"2023","journal-title":"JAAD Case Rep"},{"key":"10.25259\/IJDVL_133_2025\/ref-18","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/ced\/llad348","article-title":"JAK-ing up chronic actinic dermatitis with upadacitinib","volume":"49","author":"Pappa","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"10.25259\/IJDVL_133_2025\/ref-19","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/ced\/llad242","article-title":"Treatment of netherton syndrome with upadacitinib","volume":"48","author":"Li","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"10.25259\/IJDVL_133_2025\/ref-20","doi-asserted-by":"publisher","first-page":"AB185","DOI":"10.1016\/j.jaad.2023.07.741","article-title":"42766 JAK of all trades: Novel off-label use of the systemic jak inhibitor upadacitinib as an adjunct to systemic biologic therapy for various immune-mediated inflammatory diseases of the skin","volume":"89","author":"Abduelmula","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_133_2025\/ref-21","first-page":"280","article-title":"Response of palmoplantar pustulosis to upadacitinib","volume":"21","author":"Mohr","year":"2023","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.25259\/IJDVL_133_2025\/ref-22","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1093\/ced\/llad341","article-title":"A case of refractory generalized pustular psoriasis treated with upadacitinib","volume":"49","author":"Wang","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"10.25259\/IJDVL_133_2025\/ref-23","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jdcr.2023.03.004","article-title":"Refractory pityriasis rubra pilaris treated with upadacitinib","volume":"35","author":"Song","year":"2023","journal-title":"JAAD Case Rep"},{"key":"10.25259\/IJDVL_133_2025\/ref-24","doi-asserted-by":"publisher","first-page":"2246604","DOI":"10.1080\/09546634.2023.2246604","article-title":"Upadacitinib in nail psoriasis: A case report","volume":"34","author":"Wang","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"10.25259\/IJDVL_133_2025\/ref-25","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1111\/ddg.14612","article-title":"Alleviation of erosive oral and esophageal lichen planus by the JAK1 inhibitor upadacitinib","volume":"19","author":"Kooybaran","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.25259\/IJDVL_133_2025\/ref-26","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1080\/09546634.2022.2116926","article-title":"JAK inhibitors in lichen planus: A review of pathogenesis and treatments","volume":"33","author":"Motamed-Sanaye","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"10.25259\/IJDVL_133_2025\/ref-27","doi-asserted-by":"publisher","first-page":"2302394","DOI":"10.1080\/09546634.2024.2302394","article-title":"Upadacitinib for the management of bullous pemphigoid coexisting with psoriasis vulgaris: A case report and literature review","volume":"35","author":"Su","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"10.25259\/IJDVL_133_2025\/ref-28","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jdcr.2022.12.006","article-title":"Bullous pemphigoid treated with Janus kinase inhibitor upadacitinib","volume":"32","author":"Nash","year":"2022","journal-title":"JAAD Case Rep"},{"key":"10.25259\/IJDVL_133_2025\/ref-29","doi-asserted-by":"publisher","first-page":"881","DOI":"10.25251\/skin.7.4.5","article-title":"Oral jak inhibitor upadacitinib use in treatment of pemphigus foliaceus","volume":"7","author":"Guenin","year":"2023","journal-title":"J of Skin"},{"key":"10.25259\/IJDVL_133_2025\/ref-30","doi-asserted-by":"publisher","first-page":"AB216","DOI":"10.1016\/j.jaad.2023.07.867","article-title":"43307 Recalcitrant amyopathic dermatomyositis treated with upadacitinib","volume":"89","author":"Torre","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_133_2025\/ref-31","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.2147\/CCID.S419344","article-title":"Treatment of discoid lupus erythematosus with upadacitinib: A case report","volume":"16","author":"Hu","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.25259\/IJDVL_133_2025\/ref-32","doi-asserted-by":"publisher","first-page":"e335","DOI":"10.1111\/jdv.19604","article-title":"Efficacy of upadacitinib in a case of resistant lupus erythematosus tumidus","volume":"38","author":"Maione","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_133_2025\/ref-33","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/rheumatology\/keac440","article-title":"JAK inhibitors in difficult-to-treat adult-onset Still\u2019s disease and systemic-onset juvenile idiopathic arthritis","volume":"62","author":"Gillard","year":"2023","journal-title":"Rheumatol Oxf Engl"},{"key":"10.25259\/IJDVL_133_2025\/ref-34","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.jaad.2023.05.001","article-title":"Beneficial effects of upadacitinib on alopecia areata associated with atopic dermatitis: A multicenter retrospective study","volume":"89","author":"Chiricozzi","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_133_2025\/ref-35","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.jaad.2022.07.047","article-title":"Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study","volume":"87","author":"Kozera","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_133_2025\/ref-36","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1111\/jdv.19483","article-title":"Upadacitinib treatment associated with varicella zoster infection complicated by haemophagocytic lymphohistiocytosis in a patient with severe hidradenitis suppurativa","volume":"38","author":"Abu Rached","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_133_2025\/ref-37","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jdcr.2023.06.014","article-title":"Acne keloidalis nuchae in a patient with atopic dermatitis treated with Janus kinase inhibitor upadacitinib","volume":"38","author":"Caudrelier","year":"2023","journal-title":"JAAD Case Rep"},{"key":"10.25259\/IJDVL_133_2025\/ref-38","doi-asserted-by":"publisher","first-page":"e52377","DOI":"10.7759\/cureus.52377","article-title":"Improvement of recalcitrant dissecting cellulitis of the scalp after a trial of upadacitinib","volume":"16","author":"Islam","year":"2024","journal-title":"Cureus"},{"key":"10.25259\/IJDVL_133_2025\/ref-39","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1111\/jdv.19462","article-title":"Treatment of chronic prurigo with upadacitinib: A case series","volume":"38","author":"Gil-Lianes","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_133_2025\/ref-40","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jdcr.2023.01.037","article-title":"Upadacitinib for prurigo nodularis","volume":"48","author":"Muntaner-Virgili","year":"2023","journal-title":"JAAD Case Rep"},{"key":"10.25259\/IJDVL_133_2025\/ref-41","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.jaad.2023.07.1016","article-title":"Efficacy and tolerability of oral upadacitinib monotherapy in patients with recalcitrant vitiligo","volume":"89","author":"Su","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_133_2025\/ref-42","doi-asserted-by":"publisher","first-page":"e633","DOI":"10.1111\/jdv.18756","article-title":"Upadacitinib for treatment-resistant Lichen amyloidosis","volume":"37","author":"Solimani","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_133_2025\/ref-43","doi-asserted-by":"publisher","first-page":"e215","DOI":"10.1111\/jdv.18487","article-title":"Epidermolysis bullosa pruriginosa with extensive truncal involvement treated with upadacitinib","volume":"37","author":"Kim","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_133_2025\/ref-44","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jdcr.2023.11.024","article-title":"Letter to the editor: Effective treatment of disseminated granuloma annulare with upadacitinib","volume":"44","author":"Zheng","year":"2023","journal-title":"JAAD Case Rep"},{"key":"10.25259\/IJDVL_133_2025\/ref-45","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jdcr.2023.02.010","article-title":"Treatment of persistent erythema multiforme with upadacitinib: A novel therapeutic approach","volume":"34","author":"Deutsch","year":"2023","journal-title":"JAAD Case Rep"},{"key":"10.25259\/IJDVL_133_2025\/ref-46","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1001\/jamadermatol.2021.0996","article-title":"Treatment of severe multicentric reticulohistiocytosis with upadacitinib","volume":"157","author":"Niaki","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.25259\/IJDVL_133_2025\/ref-47","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jdcr.2022.10.010","article-title":"A case of erythrodermic mycosis fungoides responding to upadacitinib","volume":"30","author":"Castillo","year":"2022","journal-title":"JAAD Case Rep"},{"key":"10.25259\/IJDVL_133_2025\/ref-48","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1001\/jamadermatol.2024.2378","article-title":"Upadacitinib for treatment of granulomatous cheilitis","volume":"160","author":"De Greef","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.25259\/IJDVL_133_2025\/ref-49","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jdcr.2023.09.011","article-title":"Refractory Hailey\u2013Hailey disease cleared with upadacitinib","volume":"41","author":"Murphy","year":"2023","journal-title":"JAAD Case Reports"},{"key":"10.25259\/IJDVL_133_2025\/ref-50","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jdcr.2023.05.016","article-title":"Resolution of therapy-resistant pyoderma gangrenosum with upadacitinib","volume":"37","author":"Van Eycken","year":"2023","journal-title":"JAAD Case Rep"},{"key":"10.25259\/IJDVL_133_2025\/ref-51","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1111\/1756-185X.14774","article-title":"Novel JAK-1 inhibitor upadacitinib as a possible treatment for refractory SAPHO syndrome: A case report","volume":"26","author":"Ma","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"10.25259\/IJDVL_133_2025\/ref-52","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.jaci.2021.07.036","article-title":"Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results","volume":"149","author":"Silverberg","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.25259\/IJDVL_133_2025\/ref-53","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1001\/jamadermatol.2022.0029","article-title":"Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: Analysis of follow-up data from the measure up 1 and measure up 2 randomized clinical trials","volume":"158","author":"Simpson","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.25259\/IJDVL_133_2025\/ref-54","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s13555-022-00842-7","article-title":"Safety and efficacy of upadacitinib for atopic dermatitis in Japan: 2-Year interim results from the phase 3 rising up study","volume":"13","author":"Katoh","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.25259\/IJDVL_133_2025\/ref-55","doi-asserted-by":"publisher","first-page":"II65","DOI":"10.1093\/bjd\/ljad498.066","article-title":"501 - Efficacy and safety of upadacitinib in a phase 2 randomized, double-blind, dose-ranging study of adults with extensive non-segmental vitiligo","volume":"190","author":"Passeron","year":"2024","journal-title":"Br J Dermatol"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/upadacitinib-in-dermatology-a-systematic-review-of-mechanism-current-applications-efficacy-safety-and-emerging-evidence\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/upadacitinib-in-dermatology-a-systematic-review-of-mechanism-current-applications-efficacy-safety-and-emerging-evidence\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T13:02:11Z","timestamp":1767358931000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/upadacitinib-in-dermatology-a-systematic-review-of-mechanism-current-applications-efficacy-safety-and-emerging-evidence\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":55,"alternative-id":["10.25259\/IJDVL_133_2025"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_133_2025","relation":{},"ISSN":["0973-3922","0378-6323"],"issn-type":[{"value":"0973-3922","type":"electronic"},{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"article-number":"68"}}